Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) and Context Therapeutics (NASDAQ:CNTX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.
Volatility & Risk
Alaunos Therapeutics has a beta of -1.08, meaning that its share price is 208% less volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and target prices for Alaunos Therapeutics and Context Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alaunos Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
| Context Therapeutics | 0 | 0 | 4 | 1 | 3.20 |
Profitability
This table compares Alaunos Therapeutics and Context Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alaunos Therapeutics | N/A | -267.77% | -209.18% |
| Context Therapeutics | N/A | -58.76% | -55.80% |
Valuation and Earnings
This table compares Alaunos Therapeutics and Context Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alaunos Therapeutics | $11,000.00 | 465.16 | -$35.14 million | N/A | N/A |
| Context Therapeutics | N/A | N/A | -$23.96 million | ($0.31) | -2.27 |
Context Therapeutics has lower revenue, but higher earnings than Alaunos Therapeutics.
Institutional and Insider Ownership
27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by insiders. Comparatively, 2.8% of Context Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Context Therapeutics beats Alaunos Therapeutics on 8 of the 11 factors compared between the two stocks.
About Alaunos Therapeutics
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.
About Context Therapeutics
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
